As per terms of the deal, Q2 Solutions will develop NGS assays by using Illumina’s MiSeqDx instrument.

MiSeqDx is claimed to be the first NGS instrument to be cleared by the US Food and Drug Administration (FDA) for in vitro diagnostic purposes in clinical laboratories.

The partnership will allow to combine Q2 Solutions’ genomic, scientific and medical expertise with Illumina’s ability to apply innovative technologies to the analysis of genetic variation and function. 

The CDx development portfolio will allow Q2 Solutions to provide a wide range of end-to-end services ranging from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

Q2 Solutions CEO Costa Panagos said: “At Q2 Solutions, we partner with our customers to bring innovative solutions to meet the needs of patients across the world.

“The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted and accurate therapies are critical.

“Q2 Solutions helped develop 62 percent of all FDA-approved precision medicine drugs of 2015, and we look forward to the opportunity to continue working with our customers on an approach that can help improve healthcare globally.”

Q2 Solutions, which is a joint venture of QuintilesIMS and Quest Diagnostics, serves biopharmaceutical, medical device and diagnostics customers.